Trials / Completed
CompletedNCT05226442
Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Argatroban | Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects |
| DRUG | Unfractionated heparin | Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2024-07-07
- Completion
- 2024-07-07
- First posted
- 2022-02-07
- Last updated
- 2024-09-19
Locations
1 site across 1 country: Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05226442. Inclusion in this directory is not an endorsement.